<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Raltegravir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Raltegravir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Raltegravir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9451" href="/d/html/9451.html" rel="external">see "Raltegravir: Drug information"</a> and <a class="drug drug_patient" data-topicid="11998" href="/d/html/11998.html" rel="external">see "Raltegravir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5374882"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Isentress;</li>
<li>Isentress HD</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868913"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Isentress;</li>
<li>Isentress HD</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F6771674"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiretroviral Agent</span>;</li>
<li>
<span class="list-set-name">Antiretroviral, Integrase Inhibitor (Anti-HIV)</span>;</li>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">HIV Agents (Anti-HIV Agents)</span>;</li>
<li>
<span class="list-set-name">Integrase Inhibitor</span></li></ul></div>
<div class="block don drugH1Div" id="F53462649"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b391164b-a66b-4453-92e8-bcca5447d582">HIV-1 perinatal transmission, presumptive treatment; high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 perinatal transmission, presumptive treatment; high risk (3-drug regimen)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In general, therapy should be initiated as soon as possible after birth; however, if the mother received raltegravir within 2 to 24 hours prior to delivery, neonatal raltegravir administration should be delayed to 24 to 48 hours after birth; initiate other antiretrovirals as soon as possible and within 6 hours of delivery. If HIV infection is confirmed in the neonate, transition to a treatment and monitoring regimen for confirmed infection. Raltegravir is recommended as part of a 3-drug regimen for empiric treatment of HIV in neonates at high risk of perinatal transmission and also serves as HIV prophylaxis; see guidelines for additional information on high-risk definition. The full 3-drug regimen may be continued for 2 to 6 weeks depending on nucleic acid test (NAT) results, maternal viral load at delivery, and additional risk factors for HIV transmission; zidovudine should be continued for the 6 weeks even if the other two drugs are discontinued sooner (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates (≥37 weeks GA) and weighing ≥2 kg:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≤7 days: <b>Note:</b> To minimize the number of outpatient dose changes, some experts suggest increasing the dose (see "PNA 8 to 28 Days" dosing) at hospital discharge (eg, on PNA day 4 or 5) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Weight-directed dosing</i>: Oral suspension (10 mg/mL): Oral: 1.5 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Fixed dosing</i>: Oral suspension (10 mg/mL):</p>
<p style="text-indent:-2em;margin-left:10em;">2 to &lt;3 kg: Oral: 4 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to &lt;4 kg: Oral: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to &lt;5 kg: Oral: 7 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 8 to 28 days:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Weight-directed dosing</i>: Oral suspension (10 mg/mL): Oral: 3 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Fixed dosing</i>: Oral suspension (10 mg/mL):</p>
<p style="text-indent:-2em;margin-left:10em;">2 to &lt;3 kg: Oral: 8 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to &lt;4 kg: Oral: 10 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to &lt;5 kg: Oral: 15 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 29 to 42 days (≥4 to 6 weeks of age):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Weight-directed dosing</i>: Oral suspension (10 mg/mL): Oral: 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Fixed dosing</i>: Oral suspension (10 mg/mL):</p>
<p style="text-indent:-2em;margin-left:10em;">3 to &lt;4 kg: Oral: 25 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to &lt;6 kg: Oral: 30 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to &lt;8 kg: Oral: 40 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Note:</b> Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BIyhFr5DXQKXVpJHU7OxLdGQQvaV8jFf9fv%2F8URENCOd&amp;TOPIC_ID=89430" target="_blank">https://hivdb.stanford.edu</a> for more information).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates (≥37 weeks GA) and weighing ≥2 kg:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≤7 days: <b>Note:</b> If the mother received raltegravir 2 to 24 hours prior to delivery, the initial neonatal dose should be delayed until 24 to 48 hours after birth. Other ARVs should be started as soon as possible (within 6 hours after delivery) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>). To minimize the number of outpatient dose changes, some experts suggest increasing the dose (see "PNA 8 to 28 Days" dosing) at hospital discharge (eg, on PNA day 4 or 5) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Weight-directed dosing</i>: Oral suspension (10 mg/mL): Oral: 1.5 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Fixed dosing</i>: Oral suspension (10 mg/mL):</p>
<p style="text-indent:-2em;margin-left:10em;">2 to &lt;3 kg: Oral: 4 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to &lt;4 kg: Oral: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to &lt;5 kg: Oral: 7 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 8 to 28 days:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Weight-directed dosing</i>: Oral suspension (10 mg/mL): Oral: 3 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Fixed dosing</i>: Oral suspension (10 mg/mL):</p>
<p style="text-indent:-2em;margin-left:10em;">2 to &lt;3 kg: Oral: 8 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to &lt;4 kg: Oral: 10 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to &lt;5 kg: Oral: 15 mg twice daily.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F5374920"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Raltegravir film-coated tablets (including Isentress HD) and chewable tablets or oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment: Note:</b> Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BIyhFr5DXQKXVpJHU7OxLdGQQvaV8jFf9fv%2F8URENCOd&amp;TOPIC_ID=89430" target="_blank">https://hivdb.stanford.edu</a> for more information).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral suspension (10 mg/mL):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children weighing &lt;20 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-directed dosing: Oral: 6 mg/kg/dose twice daily; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Fixed dosing: Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">3 to &lt;4 kg: 25 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to &lt;6 kg: 30 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to &lt;8 kg: 40 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">8 to &lt;11 kg: 60 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">11 to &lt;14 kg: 80 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">14 to &lt;20 kg: 100 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chewable tablets:</i>
<b>Note: </b>The film-coated tablets are preferred in children and adolescents weighing ≥25 kg who are able to swallow a tablet whole.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents weighing ≥3 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-directed dosing: Oral: 6 mg/kg/dose twice daily; maximum dose: 300 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Fixed dosing: Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">3 to &lt;6 kg: 25 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to &lt;10 kg: 50 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">10 to &lt;14 kg: 75 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">14 to &lt;20 kg: 100 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">20 to &lt;28 kg: 150 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">28 to &lt;40 kg: 200 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">≥40 kg: 300 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Film-coated tablets:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Isentress: 400 mg tablets: Children and Adolescents ≥25 kg: Oral: 400 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Isentress HD: 600 mg tablets: Children and Adolescents ≥40 kg: Oral: 1,200 mg once daily. <b>Note:</b> Regimen appropriate for treatment-naive patients, or patients virologically suppressed on an initial regimen of raltegravir 400 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="609f4b69-ac8d-490c-a393-00eea46d752e">HIV-1 nonoccupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 nonoccupational postexposure prophylaxis (nPEP)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.PeP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.PeP.1'])">Ref</a></span>): <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: Oral: <i>Oral suspension (10 mg/mL):</i> 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chewable tablets:</i></p>
<p style="text-indent:-2em;margin-left:8em;">11 to &lt;14 kg: 75 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">14 to &lt;20 kg: 100 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">20 to &lt;28 kg: 150 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">28 to &lt;40 kg: 200 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: 300 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Film-coated tablet: </i>Isentress 400 mg tablet: Children ≥6 years weighing &gt;25 kg who are able to swallow a tablet whole: 400 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: <i>Film-coated tablet:</i> Isentress 400 mg tablet: 400 mg twice daily for 28 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159906"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild, moderate, or severe impairment: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Dose after dialysis on dialysis days.</p></div>
<div class="block dohp drugH1Div" id="F51159907"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Film-coated tablet (400 mg formulation at standard twice-daily dose), chewable tablet, oral suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate hepatic impairment: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Film-coated tablet (600 mg formulation [Isentress HD]): Pediatric patients ≥40 kg: Use is not recommended in any degree of hepatic impairment (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F5374921"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9451" href="/d/html/9451.html" rel="external">see "Raltegravir: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Note:</b> Do not use raltegravir in combination with darunavir and ritonavir in patients with HIV RNA &gt;100,000 copies/mL and/or CD4 count &lt;200 cells/mm<sup>3</sup>, or in combination with abacavir and lamivudine in patients with HIV RNA &gt;100,000 copies/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment-naive patients:</i>
<b>Oral:</b> Film-coated tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Isentress: 400 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients virologically suppressed on an initial regimen of raltegravir 400 mg twice daily may switch to once daily dosing with Isentress HD.</p>
<p style="text-indent:-2em;margin-left:6em;">Isentress HD: 1.2 g once daily (2 × 600 mg tablet).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Once daily dosing is not recommended for use during pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment-experienced patients</i>: <b>Oral: </b>Film-coated tablet: Isentress: 400 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="609f4b69-ac8d-490c-a393-00eea46d752e">HIV-1 nonoccupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 nonoccupational postexposure prophylaxis (nPEP) (off-label use)</b>: <b>Oral:</b> Film-coated tablet: Isentress: 400 mg twice daily for 28 days in combination with other antiretroviral agents. Initiate therapy within 72 hours of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.PeP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.PeP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="073e1ab6-e458-419d-abe6-bd0e545357ed">HIV-1 occupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 occupational postexposure prophylaxis (oPEP) (off-label use):</b>
<b>Oral:</b> Film-coated tablet: Isentress: 400 mg twice daily for 4 weeks with concomitant emtricitabine/tenofovir. Initiate therapy as soon as possible after occupational exposure (and within 72 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23917901']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23917901'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992008"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild, moderate, and severe impairment: No dosage adjustment necessary. </p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Dose after dialysis on dialysis days.</p></div>
<div class="block doha drugH1Div" id="F50989254"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Film-coated tablet (Isentress 400 mg tablet), chewable tablet, oral suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Film-coated tablet (Isentress HD 600 mg tablet): Use is not recommended (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F5374897"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reaction incidence is for combination therapy in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hepatic: Increased serum alanine aminotransferase (grade 2 to 4: ≤11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increase in fasting plasma glucose (grade 2: 126 to 250 mg/dL: 7% to 10%; grade 3: 251 to 500 mg/dL: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&lt;2%), decreased appetite (≥2%), diarrhea (≥2%), dyspepsia (&lt;2%), flatulence (≥2%), gastritis (&lt;2%), increased serum amylase (grade 2 to 4: ≤4%), increased serum lipase (grade 2 to 4: 1% to 7%), nausea (1% to 3%), vomiting (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genital herpes simplex (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decrease in absolute neutrophil count (grade 2 to 4: ≤4%), decreased hemoglobin (grade 2 to 4: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (&lt;2%), increased serum alkaline phosphatase (grade 2 to 4: ≤2%), increased serum aspartate aminotransferase (grade 2 to 4: ≤9%), increased serum bilirubin (grade 2 to 4: ≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (≥2%), asthenia, depression, dizziness (≤2%), fatigue (2%), headache (≤4%), insomnia (≤4%), nightmares (≥2%), suicidal ideation (&lt;2%), suicidal tendencies (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (grade 2 to 4: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (grade 2 to 3: ≤1%), nephrolithiasis (&lt;2%), renal failure syndrome (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Abnormal behavior (grade 3: children and adolescents), psychomotor agitation (grade 3: children and adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased HDL cholesterol, increased LDL cholesterol, increased serum cholesterol, increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant neoplasm</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (Fong 2017, O’Halloran 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilic and systemic symptoms (Perry 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immune reconstitution syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, cerebellar ataxia, paranoid ideation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy, rhabdomyolysis</p></div>
<div class="block coi drugH1Div" id="F5374893"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling: </i>Hypersensitivity to raltegravir or any other component of the formulation</p></div>
<div class="block war drugH1Div" id="F5374894"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves’ disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy: Grade 2 to 4 creatine kinase (CK) increases have been observed and myopathy and rhabdomyolysis have been reported; use caution in patients with a history of rhabdomyolysis, myopathy, or increased serum creatine kinase or who have risk factors for CK elevations and/or skeletal muscle abnormalities, including taking other drugs known to cause myopathy or rhabdomyolysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin and hypersensitivity reactions: Severe, life-threatening or fatal cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Hypersensitivity reactions (rash, constitutional symptoms, organ dysfunction) have also been reported. Discontinue immediately if a severe skin reaction or hypersensitivity symptoms develop. Monitor clinical status, including liver transaminases.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chewable tablet: Contains phenylalanine; avoid or use with caution in patient with phenylketonuria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tablets and oral suspension: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53321157"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">At birth, the enzyme responsible for the metabolism of raltegravir (UGT1A1) is low and raltegravir elimination in neonates may be prolonged. The activity of UGT1A1 increases rapidly over the first 4 to 6 weeks of life (HHS [perinatal] 2023). Raltegravir also competes with bilirubin for albumin protein-binding sites and may increase unconjugated bilirubin concentrations, which could be particularly concerning in neonates due to kernicterus risk in the presence of high raltegravir concentrations. However, in vitro data suggest that this effect is unlikely to be significant at typical serum concentrations (Clarke 2013; HHS [pediatric] 2023). Additionally, in 42 neonates who received ≤6 weeks of raltegravir therapy and were followed for 24 weeks, there were only 2 cases of nonserious bilirubin elevations for which no treatment was necessary and no drug-related clinical adverse reactions were observed.</p></div>
<div class="block foc drugH1Div" id="F5374928"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isentress: 100 mg (60 ea) [contains polyethylene glycol (macrogol); banana flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isentress: 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isentress HD: 600 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isentress: 25 mg [contains aspartame, saccharin sodium; orange banana flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isentress: 100 mg [scored; contains aspartame, saccharin sodium; orange banana flavor]</p></div>
<div class="block geq drugH1Div" id="F5374884"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F5552127"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Isentress Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $2.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $9.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Isentress Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $9.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Isentress HD Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $39.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Isentress Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $39.94</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868914"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isentress: 400 mg [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isentress HD: 600 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isentress: 25 mg, 100 mg [contains aspartame, saccharin sodium]</p></div>
<div class="block admp drugH1Div" id="F52614257"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Chewable tablets: May be chewed, crushed (25 mg), or swallowed whole; 100 mg chewable tablet can be split in half.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients unable to chew the chewable tablet</i>: The 25 mg tablet may be crushed by placing tablet and ~5 mL of liquid (eg, water, juice, breast milk) in a small cup; the tablet should break apart within 2 minutes; crush any remaining pieces of undispersed tablet with a spoon and administer the entire mixture immediately. If any dose remains in cup, add ~5 mL of liquid, swirl, and administer immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Film-coated tablets: Must be swallowed whole.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Administer dose (at a concentration of 10 mg/mL) within 30 minutes of reconstitution.</p></div>
<div class="block adm drugH1Div" id="F9613920"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Chewable tablets: May be chewed or swallowed whole; the 100 mg chewable tablet may be divided into equal halves.</p>
<p style="text-indent:-2em;margin-left:2em;">Film-coated tablets: Must be swallowed whole.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Using provided mixing cup, pour packet contents into 10 mL water, close lid and swirl in a circular motion for 45 seconds; do not shake. Do not turn the mixing cup upside down. Once mixed, measure recommended suspension dose with an oral syringe (concentration of suspension is 10 mg/mL). Administer within 30 minutes of mixing with water. Discard any remaining suspension in the trash.</p></div>
<div class="block sts drugH1Div" id="F5374908"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Film-coated and chewable tablets: Store in the original package; keep desiccant in the bottle to protect from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Store in the original container; do not open foil packet until ready for reconstitution and use.</p></div>
<div class="block usep drugH1Div" id="F53570220"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of HIV-1 infection in combination with other antiretroviral agents (Isentress: FDA approved in pediatric patients weighing ≥2 kg and adults; Isentress HD: FDA approved in pediatric patients weighing ≥40 kg and adults). <b>Note:</b> HIV regimens consisting of <b>three</b> active antiretroviral agents from at least <b>two</b> classes recommended. Has also been used for HIV-1 nonoccupational postexposure prophylaxis (nPEP) and in the management of newborns with perinatal HIV exposure.</p></div>
<div class="block cyt drugH1Div" id="F13299978"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of UGT1A1</p></div>
<div class="block dri drugH1Div" id="F5374903"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May decrease the serum concentration of Raltegravir. Management: Avoid the use of oral / enteral aluminum hydroxide with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Carbonate: May decrease the serum concentration of Raltegravir. Management: Use of once-daily raltegravir with calcium carbonate is not recommended; dose separation does not appear to be adequate to minimize the significance of this interaction. Use of other raltegravir products do not require any dose change.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Raltegravir. Management: Concurrent use of etravirine with once-daily raltegravir (Isentress HD) is not recommended. Concurrent use of other raltegravir products with etravirine does not require any dose change.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: Raltegravir may enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May decrease the serum concentration of Raltegravir. Raltegravir may decrease the serum concentration of Fosamprenavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Raltegravir may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the serum concentration of Raltegravir. Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Raltegravir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Raltegravir. Management: Increase raltegravir dose to 800 mg twice daily (adult dose) when used concomitantly with rifampin. Concurrent use of rifampin with once-daily raltegravir (Isentress HD) is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May increase the serum concentration of Raltegravir. Rifapentine may decrease the serum concentration of Raltegravir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Raltegravir. Management: Concurrent use of tipranavir/ritonavir with once-daily raltegravir (Isentress HD) is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Raltegravir may enhance the myopathic (rhabdomyolysis) effect of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F5374906"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Variable absorption depending upon meal type (low- vs high-fat meal) and dosage form. Management: Raltegravir was administered without regard to meals in clinical trials.</p></div>
<div class="block dic drugH1Div" id="F5374925"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine; avoid or use with caution in patient with phenylketonuria.</p></div>
<div class="block rep_considerations drugH1Div" id="F49321946"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;margin-top:2em;">Contraception is not required to initiate or continue antiretroviral therapy.</p>
<p style="text-indent:0em;margin-top:2em;">The US Department of Health and Human Services (HHS) perinatal HIV guidelines consider raltegravir an alternative integrase strand transfer inhibitor for patients with HIV who are not yet pregnant but are trying to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">Maximum viral suppression sustained below the limits of detection prior to conception is recommended for all persons with HIV who are planning a pregnancy. Optimization of the health of the person who will become pregnant is recommended. Selection of or changes to a specific antiretroviral regimen prior to pregnancy should be done as part of a shared decision-making process. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender-diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for couples planning a pregnancy when one or both partners are diagnosed with HIV may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block pri drugH1Div" id="F5374889"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Raltegravir has high transfer across the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">No increased risk of overall teratogenic effects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may be associated with adverse pregnancy outcomes including preterm birth, low birth weight, and small for gestational age infants. Actual risks may be influenced by maternal factors such as disease severity, gestational age at initiation of therapy, and specific ART regimen; therefore, close fetal monitoring is recommended. Because there is clear benefit to appropriate treatment, maternal ART should not be withheld due to concerns for adverse neonatal outcomes. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children not diagnosed with HIV but who were exposed to ART in utero or as a neonate and develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential metabolic dysfunction.</p>
<p style="text-indent:0em;margin-top:2em;">The US Department of Health and Human Services (HHS) Perinatal HIV Guidelines consider raltegravir an alternative integrase strand transfer inhibitor (INSTI) for pregnant patients with HIV who are antiretroviral-naive, who have had ART therapy in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). In addition, patients who become pregnant while taking raltegravir may continue if viral suppression is effective and the regimen is well tolerated. INSTIs can rapidly suppress viral load. Raltegravir may be useful as part of an alternative regimen when drug interactions or the potential for preterm delivery with protease inhibitors are a concern. In addition, use of raltegravir may be part of an alternative regimen in patients with HIV who are not on ART and present for care late in pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of raltegravir are variable. Dose adjustments are not required in pregnant patients; however, once daily dosing is not recommended until more data in pregnancy are available.</p>
<p style="text-indent:0em;margin-top:2em;">ART is recommended for all pregnant people with HIV to maximize their health, maintain the viral load below the limit of detection, and reduce the risk of perinatal transmission. Selection of or changes to a specific antiretroviral regimen during pregnancy should be done as part of a shared decision-making process. Patients on fully suppressive regimens prior to pregnancy generally may continue the same regimen considering known pregnancy outcomes and pharmacokinetic data. Monitoring of patients who are pregnant is more frequent than in patients who are not pregnant. ART initiated during pregnancy can be modified after delivery. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender-diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to ART is ongoing. Health care providers should enroll all patients exposed to antiretroviral medications during pregnancy in the Antiretroviral Pregnancy Registry (1-800-258-4263). Enrollment should be done as early in pregnancy as possible.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for pregnant patients with HIV and their infants may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block mopp drugH1Div" id="F53570221"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">HIV: General recommendations: Management of HIV infection requires extensive monitoring; refer to current guidelines (<a href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=89430" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines</a>) for additional guidance. Antiretroviral (ARV) drug-resistance testing is recommended before initiation of therapy in treatment-naive patients and before changing regimens in patients for whom therapy has failed. After initiation of or change in ARV therapy regimen, pediatric patients should be evaluated for clinical adverse effects and treatment adherence at 1 to 2 weeks, and laboratory testing for drug toxicity should occur at 2 to 4 weeks; monitor for therapy adherence, effectiveness, and toxicities every 3 to 4 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Drug-specific monitoring: Frequency may vary based on several factors including age, concomitant therapy, and clinical response; refer to current guidelines for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">Bilirubin (at baseline and periodically during therapy during the first month of life), hepatic function tests (aminotransferases) and bilirubin (baseline, periodically during therapy for patients with underlying liver disease or concomitant hepatotoxic medications, and if clinical presentation indicates need for others), creatine phosphokinase (periodically during therapy or if clinical presentation indicates need), platelets (if clinical presentation indicates need).</p></div>
<div class="block rerp drugH1Div" id="F54475467"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Desired trough concentration: &gt;20 ng/mL; based on data from adults in which patients receiving once-daily dosing with trough concentrations &lt;20 ng/mL were at the highest risk of treatment failure (HHS [pediatric] 2023); in the evaluation of neonatal raltegravir dosing in IMPACT P1110, the target exposure for efficacy was trough concentration &gt;33 ng/mL, and the target exposures for safety were C<sub>max</sub> ≤8.7 mg/L, AUC<sub>24</sub> 12 to 40 mg•hour/L, and AUC<sub>12</sub> 6 to 20 mg•hour/L (Clarke 2019).</p></div>
<div class="block pha drugH1Div" id="F5374909"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Incorporation of viral DNA into the host cell’s genome is required to produce a self-replicating provirus and propagation of infectious virion particles. The viral cDNA strand produced by reverse transcriptase is subsequently processed and inserted into the human genome by the enzyme HIV-1 integrase (encoded by the pol gene of HIV). Raltegravir inhibits the catalytic activity of integrase, thus preventing integration of the proviral gene into human DNA.</p></div>
<div class="block phk drugH1Div" id="F5374911"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The pharmacokinetic profile of raltegravir in pediatric patients receiving recommended doses was similar to that observed in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Film-coated tablet (400 mg formulation): AUC increased twofold with high-fat meal; Chewable tablet: AUC decreased by ~6% with high-fat meal (not clinically significant); Oral suspension: The effect of food was not studied.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~83%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic glucuronidation mediated by UGT1A1.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 600 mg film-coated tablet, chewable tablet, and oral suspension have higher bioavailability compared to 400 mg film-coated tablet; dosage forms are not interchangeable.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (GA ≥37 weeks):</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≤48 hours: Single dose: Geometric mean range: 14.4 to 15.8 hours (Clarke 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 15 to 18 days: Geometric mean range: 2.5 to 2.9 hours (Clarke 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 to &lt;6 years: Median: 3.1 hours (Nachman 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Median range: 2.9 to 3.8 hours (Nachman 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Film-coated tablet (400 mg formulation): ~3 hours; film-coated tablet (600 mg formulation): ~1.5 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~51%, as unchanged drug); urine (~32%; 9% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51221454"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: At birth, the enzyme responsible for the metabolism of raltegravir (UGT1A1) is low and raltegravir elimination in neonates may be prolonged. The activity of UGT1A1 increases rapidly over the first 4 to 6 weeks of life (HHS [perinatal] 2023). Raltegravir also competes with bilirubin for albumin protein-binding sites and may increase unconjugated bilirubin concentrations (HHS [perinatal] 2023).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6875348"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Isentress hd</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Isentress | Neovir 400</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Isentress | Zepdon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Isentress | Isentress hd | Issentress</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Isentress | Isentress HD</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Isentress</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HHS.PeP.1">
<a name="HHS.PeP.1"></a>Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services (HHS). Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. <a href="https://stacks.cdc.gov/view/cdc/38856" target="_blank">https://stacks.cdc.gov/view/cdc/38856</a>. Published April 18, 2016. Accessed July 11, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31913995">
<a name="31913995"></a>Clarke DF, Acosta EP, Cababasay M, et al. Raltegravir (RAL) in neonates: dosing, pharmacokinetics (PK), and safety in HIV-1-exposed neonates at risk of infection (IMPAACT P1110). <i>J Acquir Immune Defic Syndr</i>. 2020;84(1):70-77. doi:10.1097/QAI.0000000000002294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/31913995/pubmed" id="31913995" target="_blank">31913995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31658182">
<a name="31658182"></a>Clarke DF, Mirochnick M, Acosta EP, et al. Use of modeling and simulations to determine raltegravir dosing in neonates: a model for safely and efficiently determining appropriate neonatal dosing regimens: IMPAACT P1110. <i>J Acquir Immune Defic Syndr</i>. 2019;82(4):392-398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/31658182/pubmed" id="31658182" target="_blank">31658182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23470680">
<a name="23470680"></a>Clarke DF, Wong RJ, Wenning L, Stevenson DK, Mirochnick M. Raltegravir in vitro effect on bilirubin binding. <i>Pediatr Infect Dis J</i>. 2013;32(9):978-980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/23470680/pubmed" id="23470680" target="_blank">23470680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32675580">
<a name="32675580"></a>Feiterna-Sperling C, Bukkems VE, Teulen MJA, Colbers AP; PANNA network. Low raltegravir transfer into the breastmilk of a woman living with HIV. <i>AIDS</i>. 2020;34(12):1863-1865. doi:10.1097/QAD.0000000000002624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/32675580/pubmed" id="32675580" target="_blank">32675580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27733708">
<a name="27733708"></a>Fong PS, Flynn DM, Evans CD, Korthuis PT. Integrase strand transfer inhibitor-associated diabetes mellitus: a case report. <i>Int J STD AIDS</i>. 2017;28(6):626-628. doi:10.1177/0956462416675107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/27733708/pubmed" id="27733708" target="_blank">27733708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17434401">
<a name="17434401"></a>Grinsztejn B, Nguyen BY, Katlama C, et al, “Safety and Efficacy of the HIV-1 Integrase inhibitor Raltegravir (MK-0518) in Treatment-Experienced Patients with Multidrug-Resistant Virus: A Phase II Randomised Controlled Trial,” <i>Lancet</i>, 2007, 369(9569):1261-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/17434401/pubmed" id="17434401" target="_blank">17434401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf" target="_blank">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>. Updated December 18, 2019. Accessed December 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isentress.1">
<a name="Isentress.1"></a>Isentress (raltegravir) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isentress.2">
<a name="Isentress.2"></a>Isentress (raltegravir) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17591678">
<a name="17591678"></a>Kassahun K, McIntosh I, Cui D, et al, “Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme,” <i>Drug Metab Dispos</i>, 2007, 35(9):1657-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/17591678/pubmed" id="17591678" target="_blank">17591678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32448902">
<a name="32448902"></a>Krogstad P, Samson P, Acosta EP, et al. Pharmacokinetics and safety of a raltegravir-containing regimen in children aged 4 weeks to 2 years living with human immunodeficiency virus and receiving rifampin for tuberculosis. <i>J Pediatric Infect Dis Soc</i>. Published online May 25, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/32448902/pubmed" id="32448902" target="_blank">32448902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23917901">
<a name="23917901"></a>Kuhar DT, Henderson DK, Struble KA, et al, "Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis," <i>Infect Control Hosp Epidemiol</i>, 2013, 34(9): 875-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/23917901/pubmed" id="23917901" target="_blank">23917901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19647866">
<a name="19647866"></a>Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. <i>Lancet</i>. 2009;374(9692):796-806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/19647866/pubmed" id="19647866" target="_blank">19647866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nachman.1">
<a name="Nachman.1"></a>Nachman S, Acosta E, Zheng N, et al, “Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (CT) Formulation in Children 2-5 Years,” 18th Conference on Retroviruses and Opportunistic Infections (CROI), 2011 [Poster abstract 715 from 2011 CROI Conference]</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24145879">
<a name="24145879"></a>Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. <i>Clin Infect Dis</i>. 2014;58(3):413-422. doi:10.1093/cid/cit696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/24145879/pubmed" id="24145879" target="_blank">24145879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17503547">
<a name="17503547"></a>Nair V and Chi G, “HIV Integrase Inhibitors as Therapeutic Agents in AIDS,” <i>Rev Med Virol</i>, 2007, 17(4):277-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/17503547/pubmed" id="17503547" target="_blank">17503547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35521785">
<a name="35521785"></a>O'Halloran JA, Sahrmann J, Parra-Rodriguez L, et al. Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with HIV. <i>Clin Infect Dis</i>. 2022;ciac355. doi:10.1093/cid/ciac355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/35521785/pubmed" id="35521785" target="_blank">35521785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23970584">
<a name="23970584"></a>Perry ME, Almaani N, Desai N, Larbalestier N, Fox J, Chilton D. Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety. <i>Int J STD AIDS</i>. 2013;24(8):639-42. doi: 10.1177/0956462413481528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raltegravir-pediatric-drug-information/abstract-text/23970584/pubmed" id="23970584" target="_blank">23970584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Available at <a href="http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php" target="_blank">http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php</a>. Last modified December 2013. Accessed December 30, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teppler.1">
<a name="Teppler.1"></a>Teppler H, Thompson K, Chain A, Mathe M, Nachman S, Clarke D. Crushing of raltegravir (RAL) chewable tablets for administration in infants and young children. 9th International Workshop on HIV Pediatrics 2017. 21-22 July 2017. Paris. Poster abstract 37.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines</a>. Updated April 7, 2021. Accessed July 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.6">
<a name="HHS.6"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines</a>. Updated April 11, 2023. Accessed May 25, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL_2020.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL_2020.pdf</a>. Updated December 29, 2020. Accessed January 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated December 30, 2021. Accessed January 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 89430 Version 223.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
